Search research articles
Contact Us
Filters
Showing results (131-140 of 215) with videos related to
Page
of 22
Sort By:
Gynecologic Oncology
|
June 8, 2024
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial
Rachel A Pozzar, Andrea C Enzinger, Catherine Howard, et al.
Cancer
|
April 8, 2015
NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer
Akila N Viswanathan, Jennifer Moughan, Brigitte E Miller, et al.
Gynecologic Oncology
|
February 27, 2021
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors
Elizabeth Schrier, Niya Xiong, Embree Thompson, et al.
Cancer
|
September 8, 2016
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
Vicky Makker, Fernando O Recio, Ling Ma, et al.
Gynecologic Oncology
|
July 15, 2014
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
Richard T Penson, Kathleen M Moore, Gini F Fleming, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2016
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer
Larissa A Meyer, Angel M Cronin, Charlotte C Sun, et al.
Frontiers in Oncology
|
June 18, 2015
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
Jung-Min Lee, Jane B Trepel, Peter Choyke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 30, 2023
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Ursula A Matulonis, Domenica Lorusso, Ana Oaknin, et al.
Gynecologic Oncology
|
October 26, 2024
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary
Kathleen N Moore, Domenica Lorusso, Ana Oaknin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2009
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
Ursula A Matulonis, Suzanne Berlin, Percy Ivy, et al.
Page
of 22
Search research articles
Search
Showing results (131-140 of 215) with videos related to
Sort By:
Page
of 22
Gynecologic Oncology
|
June 8, 2024
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial
Rachel A Pozzar, Andrea C Enzinger, Catherine Howard, et al.
Cancer
|
April 8, 2015
NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer
Akila N Viswanathan, Jennifer Moughan, Brigitte E Miller, et al.
Gynecologic Oncology
|
February 27, 2021
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors
Elizabeth Schrier, Niya Xiong, Embree Thompson, et al.
Cancer
|
September 8, 2016
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
Vicky Makker, Fernando O Recio, Ling Ma, et al.
Gynecologic Oncology
|
July 15, 2014
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
Richard T Penson, Kathleen M Moore, Gini F Fleming, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2016
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer
Larissa A Meyer, Angel M Cronin, Charlotte C Sun, et al.
Frontiers in Oncology
|
June 18, 2015
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
Jung-Min Lee, Jane B Trepel, Peter Choyke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 30, 2023
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Ursula A Matulonis, Domenica Lorusso, Ana Oaknin, et al.
Gynecologic Oncology
|
October 26, 2024
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary
Kathleen N Moore, Domenica Lorusso, Ana Oaknin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2009
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
Ursula A Matulonis, Suzanne Berlin, Percy Ivy, et al.
Page
of 22